Rigel Pharmaceuticals Inc News - RIGL | ADVFN

Register to chat with like-minded investors on our interactive forums.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Rigel Pharmaceuticals Inc (RIGL)
Rigel Pharmaceuticals Inc (RIGL) News

Rigel Pharmaceuticals Inc (RIGL)

20.54

0.34

(1.68%)

Closed March 24 4:00PM

Delayed by 15 minutes

20.54

0.00

( 0.00% )

Pre Market: 6:57AM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors PR Newswire SOUTH SAN FRANCISCO, Calif., March 10...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR...

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

1
Next

dcaf7

dcaf7 11 months ago

Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.

Monksdream

Monksdream 11 months ago

Monksdream

Monksdream 12 months ago

dcaf7

dcaf7 12 months ago

Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/

dcaf7

dcaf7 12 months ago

Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.

dcaf7

dcaf7 1 year ago

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023

bme

bme 2 years ago

Rigl should be VTGN (Today) one day.

bme

bme 2 years ago

Yeah. Should be good Q.

TucsonPhil

TucsonPhil 2 years ago

Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.

bme

bme 2 years ago

Better be good.

bme

bme 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

bme

bme 2 years ago

What a shoot! Amazing.

bme

bme 2 years ago

The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

bme

bme 2 years ago

Nice spike AH today.

bme

bme 2 years ago

Higher low higher low.... next leg is North.

The Night Stalker

The Night Stalker 2 years ago

https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100

The Night Stalker

The Night Stalker 2 years ago

https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100

bme

bme 2 years ago

acting wild atm, but still healthy.

The Night Stalker

The Night Stalker 2 years ago

bme

bme 2 years ago

Nice & Healthy.

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

bme

bme 2 years ago

The Night Stalker

The Night Stalker 2 years ago

The Night Stalker

The Night Stalker 2 years ago

bme

bme 2 years ago

Expect Q4 filing this week?

bme

bme 2 years ago

Be seeing that. Lot of 1.95 transactions so far

TucsonPhil

TucsonPhil 2 years ago

Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.

bme

bme 2 years ago

SP should be a lot higher since the Q4 revenue is more than double from last year...

Welldoctor

Welldoctor 2 years ago

Apparently insider buying reported on ST. Take it for what it’s worth.

Welldoctor

Welldoctor 2 years ago

bme

bme 2 years ago

Looks like it will poke thru & bye bye 1 today.

doesitreallymatter

doesitreallymatter 2 years ago

Just like ABQQ. Right?

subslover

subslover 2 years ago

You are 1/2 way there!!!!

KngmAz

KngmAz 2 years ago

Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!

KngmAz

KngmAz 2 years ago

This is a $10.00 per share stock in the very near future - EASILY!!

Alaska40

Alaska40 2 years ago

I just bought in. Seems like a good run could come in the near future.

subslover

subslover 2 years ago

Consolidating nicely on Continuation from last week!

bcapps66

bcapps66 2 years ago

THEMASTERS_SON

THEMASTERS_SON 2 years ago

GIVE ME MY $2DOLLAS…YA BUM

Rigel Pharmaceuticals

Gran Tierra Energy

Franchi Umberto Marmi

Amundi ETF FTSE MIB UCIT...

Fidelis Insurance

Accredited Solutions (PK)

Critical Metals

MaxRets Ventures

Delayed Upgrade Clock